Skip to content

Study · Measured the body's own peptide · 2018

3 results

Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.

Mangkhang K, Punyapornwithaya V, Tankaew P, Pongkan W, Chattipakorn N, Boonyapakorn C

Polish journal of veterinary sciences1 Dec 2018Cited by 6 (Europe PMC)

PMID30605282 (opens in a new tab)DOI10.24425/124305 (opens in a new tab)PepBankPUB-30605282
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In dogs with myxomatous mitral valve disease, plasma levels of the body's own humanin were lower than in healthy dogs.

    In plain wordsIn dogs with a heart valve disease, the body's own humanin in blood was lower than in healthy dogs.

    Peptide
    Humanin
    Outcome
    DecreasePlasma humanin level in dogs with MMVD
    Study

    dogn = 31

    Comparator
    Healthy dogs
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    The results showed that plasma HN levels were lower in the dogs with MMVD and that lower plasma HN levels were associated with greater severity of MMVD-induced HF.
    1 context sentence
    Summary · context
    The dogs were separated into four groups: Group 1 was healthy dogs (n = 8), Group 2 was MMVD class B (n = 8), Group 3 was MMVD class C (n = 8), and Group 4 was MMVD class D (n = 7).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In dogs with myxomatous mitral valve disease, lower plasma humanin levels were associated with greater severity of heart failure.

    In plain wordsIn dogs with a heart valve disease, lower natural humanin levels in blood were linked to more severe heart failure.

    Peptide
    Humanin
    Outcome
    DecreasePlasma humanin level by severity of MMVD-induced heart failure
    Study

    dogn = 31

    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    The results showed that plasma HN levels were lower in the dogs with MMVD and that lower plasma HN levels were associated with greater severity of MMVD-induced HF.
    1 context sentence
    Summary · context
    The dogs were separated into four groups: Group 1 was healthy dogs (n = 8), Group 2 was MMVD class B (n = 8), Group 3 was MMVD class C (n = 8), and Group 4 was MMVD class D (n = 7).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In dogs with myxomatous mitral valve disease, changes in plasma humanin levels were seen at a less severe disease stage than changes in plasma NT-proBNP.

    In plain wordsIn dogs with a heart valve disease, natural humanin levels in blood changed at an earlier disease stage than the marker NT-proBNP.

    Peptide
    Humanin
    Outcome
    Not applicableStage at which plasma humanin changes compared with NT-proBNP
    Study

    dogn = 31

    Comparator
    Plasma NT-proBNP
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    It was possible to observe changes in plasma HN levels at a less severe disease stage than plasma NT-proBNP in dogs with MMVD.
    1 context sentence
    Summary · context
    The dogs were separated into four groups: Group 1 was healthy dogs (n = 8), Group 2 was MMVD class B (n = 8), Group 3 was MMVD class C (n = 8), and Group 4 was MMVD class D (n = 7).

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.